UPDATE | September 10, 2020

Automation Offers Path to Efficiency and Data Integrity

  • MAIL
Samsung Biologics employees inspecting biopharmaceutical production facilities

Samsung Biologics, a CDMO, last month announced plans for a factory, describing it as its “P4 super plant” and citing growing demand for biopharmaceutical production capacity as the driver for the investment.


All rights are reserved by the media that published this article. 
Samsung Biologics employees inspecting biopharmaceutical production facilities

Samsung Biologics, a CDMO, last month announced plans for a factory, describing it as its “P4 super plant” and citing growing demand for biopharmaceutical production capacity as the driver for the investment.


All rights are reserved by the media that published this article. 
  • CDO
  • CGMP
  • ADC
  • Bio Campus
  • IR
  • CMO

Share article

  • MAIL

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Interests
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy required